General Information of Drug (ID: DM2NTBL)

Drug Name
PF-05241328 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Phase 1 [1]
Cross-matching ID
PubChem CID
68109743
CAS Number
CAS 1387633-03-5
TTD Drug ID
DM2NTBL
VARIDT Drug ID
DR01057

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
XEN-402 DMR69CG Osteoarthritis FA00-FA05 Phase 2 [3]
PF-05089771 DMD74BJ Chronic pain MG30 Phase 2 [4]
BIIB074 DMLV1ET Bipolar disorder 6A60 Phase 2 [5]
DSP-2230 DM0WTMD Neuropathic pain 8E43.0 Phase 1 [5]
BIIB095 DMUC6EP Pain MG30-MG3Z Phase 1 [5]
GDC0310 DMUNFEP Chronic pain MG30 Phase 1 [6]
DSP-3905 DMYHU24 Neuropathic pain 8E43.0 Phase 1 [5]
DWJ-208 DMQKDJZ Cancer related pain MG30 Phase 1 [5]
RG7893 DM1R4MQ Pain MG30-MG3Z Phase 1 [7]
PF-05186462 DMUF6W9 Pain MG30-MG3Z Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.7 (SCN9A) TT4G2JS SCN9A_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT01165736) To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity. U.S. National Institutes of Health.
2 Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
3 Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
4 Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
5 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875)